Unpacking the Legal Fallout of a Disgraced Drugmaker

This chapter explores the groundbreaking investigation into INSYS, focusing on how federal authorities relied on a whistleblower to build their case against the drugmaker's executives. It also examines the broader consequences of the opioid epidemic and raises critical questions about pharmaceutical influence in medical education.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app